Get the Stockscreener App
11.52
3.46%
0.385
Keros Therapeutics Inc Stock (KROS) Latest News
SG Americas Securities LLC Buys Shares of 24,493 Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Examining Keros Therapeutics Inc (KROS) stock is warranted - US Post News
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cantor Fitzgerald Downgrades Keros Therapeutics Inc (KROS) to a Neutral from an Overweight - Knox Daily
An analyst sees good growth prospects for Keros Therapeutics Inc (KROS) - SETE News
SG Americas Securities LLC Takes Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Exchange Traded Concepts LLC Makes New $99,000 Investment in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Markets Insider
Keros Therapeutics CEO to Speak at Biotech Conference - TipRanks
Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference - The Manila Times
Exclusive: Keros CEO Reveals Next Steps in TGF-ß Innovation at Guggenheim Conference - StockTitan
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock? - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation - Markets Insider
KROS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Keros Therapeutics, Inc. and Encourages Investors to Contact the Firm - ACCESS Newswire
When (KROS) Moves Investors should Listen - Stock Traders Daily
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation - Markets Insider
Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why - MSN
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Assenagon Asset Management S.A. Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Assenagon Asset Management S.A. Sells 158,767 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
KEROS ALERT: Bragar Eagel & Squire, P.C. is Investigating Keros Therapeutics, Inc. on ... - The Bakersfield Californian
Keros Therapeutics seals $200M deal with Takeda - MSN
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes - MSN
Keros Therapeutics (NASDAQ:KROS) Rating Lowered to Neutral at Cantor Fitzgerald - Defense World
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Keros Therapeutics, Inc. (KROS) - Business Wire
Keros Therapeutics seals $200M deal with Takeda By Investing.com - Investing.com Australia
Cantor Fitzgerald Estimates KROS FY2025 Earnings - MarketBeat
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - GlobeNewswire
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
Cantor Fitzgerald Downgrades Keros Therapeutics (KROS) - MSN
Keros Therapeutics stock rating cut to Neutral, cites dosing setback - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc.KROS - PR Newswire
Keros spikes as Teva deal takes effect; Cantor downgrades on trial setback - MSN
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Keros stock spikes as Teva deal takes effect (KROS:NASDAQ) - Seeking Alpha
Keros stock climbs on Takeda deal effectiveness - MSN
Keros Therapeutics (NASDAQ:KROS) Lowered to Neutral Rating by Cantor Fitzgerald - MarketBeat
Keros Therapeutics stock rating cut to Neutral, cites dosing setback By Investing.com - Investing.com Canada
Keros Therapeutics Secures $200M Upfront Payment in Major Takeda Licensing Deal for Elritercept - StockTitan
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):